Benjamin J. Zeskind - Jul 29, 2021 Form 3 Insider Report for Immuneering Corp (IMRX)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Stock symbol
IMRX
Transactions as of
Jul 29, 2021
Transactions value $
$0
Form type
3
Date filed
7/29/2021, 08:52 PM
Next filing
Aug 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IMRX Class A Common Stock 2.55M Jul 29, 2021 Direct
holding IMRX Class A Common Stock 545K Jul 29, 2021 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMRX Stock Option Jul 29, 2021 Class A Common Stock 210K $3.01 Direct F2
holding IMRX Stock Option Jul 29, 2021 Class A Common Stock 175K $9.74 Direct F3
holding IMRX Series A Preferred Stock Jul 29, 2021 Class A Common Stock 40.9K Direct F4
holding IMRX Series B Preferred Stock Jul 29, 2021 Class A Common Stock 8.17K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.
F2 The option has fully vested and is currently exercisable.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on May 4, 2022 and then in equal monthly installments over the subsequent three years, subject to Dr. Zeskind's continued employment through each applicable vesting date.
F4 Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.

Remarks:

Exhibit 24 - Power of Attorney